Open AccessSafety of a dust mite extract in severe allergic asthma
Author(s) -
GonzálezPérez Ruperto,
PozaGuedes Paloma,
SánchezMachín Inmaculada,
Matheu Victor
Publication year - 2013
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-3-s1-p30
Subject(s) - medicine , fluticasone propionate , asthma , mite , allergy , adverse effect , maintenance dose , house dust mite , immunotherapy , allergen , budesonide , mometasone furoate , formoterol , allergen immunotherapy , corticosteroid , immunology , botany , cancer , biology
Methods We selected 3 adult patients with a confirmed diagnosis of severe persistent allergic asthma (ATS criteria for severe asthma) for at least five years. Mean average topical steroid (inhaled) daily dose was above 1000 mcg of fluticasone propionate or 1600 mcg of budesonide. All patients included in the current trial were clinically relevant sensitized to dust mites (Dermatophagoides spp.) as shown by skin prick test and/or specific IgE. Inclusion criteria required no hospital or emergency admissions for the last 2 months with no changes in their daily medication in the last four weeks prior to the administration of immunotherapy. No pre-treatment with systemic steroids and/ or antihistaminics were used. Modified standardized specific dust mites immunotherapy extracts were subcutaneously administered according to a validated protocol to achieve a final dose of 100 DDP/ml in a two-week cluster schedule. None of the subjects in both groups have been previously treated with omalizumab. Clinical observation and lung function was strictly monitored in all subjects until the maintenance dose of immunotherapy was reached.